Compare BIO-TECHNE Corp (TECH) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? BIO-TECHNE Corp trades at $71.63 (market cap $11.16B), while Vertex Pharmaceuticals Incorporated trades at $480.98 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 10.9× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| TECH | VRTX | |
|---|---|---|
Market Cap | $11.16B | $121.95B |
Sector | Health | Health |
52-Week High | $72.12 | $529.59 |
52-Week Low | $43.31 | $366.54 |
Enterprise Value | $11.24B | $116.69B |
Dividend Yield | 0.45% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
